Brief: Transcode Therapeutics Has Regained Compliance With Minimum Bid Price Requirement Set Forth In Nasdaq Listing Rule 5550(A)(2)
07/06/2024 21:12
June 7 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS : HAS REGAINED COMPLIANCE WITH
MINIMUM
BID PRICE REQUIREMENT SET FORTH IN NASDAQ LISTING RULE
5550(A)(2)
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors